Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Cheminant, Morgane  [Clear All Filters]
Journal Article
Cheminant M, Fox TA, Alligon M, Bouaziz O, Neven B, Moshous D, Blanche S, Guffroy A, Fieschi C, Malphettes M, et al. Allogeneic stem cell transplantation compared to conservative management in adults with inborn errors of immunity. Blood. 2022.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Author Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2024.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Axicabtagene ciloleucel in large B cell lymphoma ineligible for autologous stem cell transplantation: the phase 2 ALYCANTE trial. Nat Med. 2023.
Hermine O, Jiang L, Walewski J, Bosly A, Thieblemont C, Szymczyk M, Pott C, Salles G, Feugier P, Hübel K, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2022:JCO2201780.
Sarkozy C, Thieblemont C, Obéric L, Moreau A, Bouabdallah K, Damaj G, Gastinne T, Tessoulin B, Ribrag V, Casasnovas O, et al. Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study. J Clin Oncol. 2023:JCO2301586.
Houot R, Bachy E, Cartron G, Gros F-X, Morschhauser F, Obéric L, Gastinne T, Feugier P, Duléry R, Thieblemont C, et al. Publisher Correction: Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial. Nat Med. 2023.
Camus V, Thieblemont C, Gaulard P, Cheminant M, Casasnovas R-O, Ysebaert L, Damaj GLaurent, Guidez S, Pica GMatteo, Kim WSeog, et al. Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial. J Clin Oncol. 2024:JCO2301687.